{"ticker": {"uuid": "d302e92e-0d9f-411a-8823-7efba73d07cd", "symbol": "BMY", "name": "Bristol-Myers Squibb Company", "exchange": "NYSE", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - General"}, "articles": [{"title": "PensionDanmark Pensionsforsikringsaktieselskab Buys 38,596 Shares of Bristol Myers Squibb Company $BMY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOVm40Y19KdEItcUtrZmpKa3JBeWcxTUM0WVN6YVpOZEc1cEJDN3FyTDlienMwbExlRG91bkwzbEtpdGZkZTBPR1RrdHFaTFo0OTM0UTF1eDdGZ1dYR3M0UnE2SlVwb3ctcnlodmJGSkRTNkNEZTBodUxNUldZcjJRM1dTNjZBd2FkTlZaVVVQQV9penYtTzl4ODJYQi1UT3MzVjFGeUtUTDBhX3F1LTkwUGtvaHA1SWZGY1BBeF9FU0QxZnVRLS1wWElmX3VHMWxEU052bF9iMVgxRWd0c3Jma2ZDRTJoV0x0M1lNX1RTdUxHSGc?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T21:40:05+00:00", "published_display": "07 Aug 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Czech National Bank Purchases 26,627 Shares of Bristol Myers Squibb Company $BMY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdC11X2xPQVNnaDltQVpsRWFEbDJPRjNpT0sxdTdTeHlLNXNDWV9qNXFjMlNxdGxXeGV3UUkxSks2alN5MFZsVG56R29OdkltYnN4bFhadHJkXzZIaklBc3YyS0JsRzhEQVdja3FwWDhudlZsSFRyREVIRktZb0cyTlJOVWZZeVBsMEtKTm1xLWF6ek1uZTN0NDAyMTdQdWdIb2V1N3ZfcDl6M3hPNGR3ZHhDcXZkWWdZTHlsbG9qTmstTnVxRTJ3a25HN21iZDlaOWxCYWpR?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T10:52:41+00:00", "published_display": "07 Aug 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Replimune's skin cancer drug after prior rejections", "summary": "The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Bio", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-replimunes-skin-cancer-drug-2026-08-06/", "source_name": "Reuters", "published_at": "2026-08-06T20:26:00", "published_display": "06 Aug 2026 20:26", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deal or No Deal, AstraZeneca Stock Is a Bargain", "summary": "AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are dow", "url": "https://www.wsj.com/finance/deal-or-no-deal-astrazeneca-stock-is-a-bargain-b9ce6b31", "source_name": "WSJ", "published_at": "2026-08-06T09:39:46", "published_display": "06 Aug 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyond the Megamerger: How Rumored AstraZeneca\u2013BMS Discussions Signal a New Era of Pharmaceutical Competition", "summary": "Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabiliti", "url": "https://www.pharmexec.com/view/megamerger-astrazeneca-bms-pharmaceutical-competition", "source_name": "Pharmaceutical Executive", "published_at": "2026-08-06T07:07:18", "published_display": "06 Aug 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schr\u00f6dinger (SDGR) Is Up 8.5% After AI Co\u2011Scientist Deal With BMS And Q2 Profitability Shift \u2013 Has The Bull Case Changed?", "summary": "Schr\u00f6dinger, Inc. reported strong Q2 2026 results with a shift to profitability and a significant expansion of its AI co-scientist collaboration with Bristol Myers Squibb. This deal, involving the new agentic AI Bunsen, reinforces the company's AI-driven growth ambitions and its ", "url": "https://ca.finance.yahoo.com/news/schr-dinger-sdgr-8-5-060952292.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-06T06:12:34", "published_display": "06 Aug 2026 06:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Looks Reasonable Below Fair Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxQU1ZycklqWlFQMkxjU0lrUTJEUlMwOWFQQ3hwRU42bzBYa1pYLUdWYVhwX0lJazVKQWxMcFNnNHdxRGtTaGNfbHZhZ2tmSVRiTlpjZXdrZVhaX2FFR1FNbzBfWVlUUUZ1ZlcwSHhLVVc5QVZtR0hvblRkSFd2c3F0eG9VUXhhOGRhNFBhSTZ2eW1TZDNrVTV4OXZlQXpvWnhFc3lOMGp2ZWZWcjdYbnYzMXhYbnZZQVoxMDJSMjFUQTNlSEc2ZUJhdWZ3bThxemprV3hBTngxc0IzcWF6THlGY3JwM2l5YVFBRmNJ0gHrAUFVX3lxTFBTVnJySWpaUVAyTGNTSWtRMkRSUzA5YVBDeHBFTjZvMFhrWlgtR1ZhWHBfSUlrNUpBbExwU2c0d3FEa1NoY19sdmFna2ZJVGJOWmNld2tlWFpfYUVHUU1vMF9ZWVRRRnVmVzBIeEtVVzlBVm1HSG9uVGRIV3ZzcXR4b1VReGE4ZGE0UGFJNnZ5bVNkM2tVNXg5dmVBem9aeEVzeU4wanZlZlZyN1hudjMxeFhudllBWjEwMlIyMVRBM2VIRzZlQmF1ZndtOHF6amtXeEFOeDFzQjNxYXpMeUZjcnAzaXlhUUFGY0k?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-06T04:48:41+00:00", "published_display": "06 Aug 2026 04:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sources quash rumours of an AZ/BMS mega-merger", "summary": "Reports from Reuters indicate there is no truth to the rumors of a potential $400 billion mega-merger between AstraZeneca (AZ) and Bristol Myers Squibb (BMS). A senior source close to the matter confirmed that no such deal was ever contemplated, nor are there ongoing discussions ", "url": "https://pharmaphorum.com/news/sources-quash-rumours-azbms-mega-merger", "source_name": "pharmaphorum", "published_at": "2026-08-06T05:37:15", "published_display": "06 Aug 2026 05:37", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation", "summary": "AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, wh", "url": "https://www.pymnts.com/cpi-posts/astrazeneca-bristol-myers-dismiss-merger-talk-speculation/", "source_name": "PYMNTS.com", "published_at": "2026-08-06T03:07:17", "published_display": "06 Aug 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Co (BMY) Stock Down 3.4% but Still Overvalued -- GF Score: 71/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOUEdUOWJjSUFNaGNrM2dCb2xieDhHcnRPcjRrb1MyNGV2YWtxRDNhZ044TmIyd1RxWDdHT3pMWVQ4bnh4ZENOazZQUGg4dEZPNko2bUlZVzJIQjcwLTNWbHRtamhrNnZETmNfVnZSbWpLSTg1dlRqNUJ1M3NFcWZBQVYwNW9VdjgwUXJReENFS3JfaTNFQVhBd0RoclhjZVJVVmxwWjJ2TEIwNi1TaElTRlI3c1Rfdw?oc=5", "source_name": "GuruFocus", "published_at": "2026-08-05T21:35:11+00:00", "published_display": "05 Aug 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Company (BMY) Stock Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOanE0TldodlF3REExQUR3OUprMElfY29lU0tGaDlFNmJvU2xHSTI1VGE2OFpwdjYwbTRUQUVMUGEzSWNMVHVsYXdVbXdhVFo3QzAxMlRzcVJiT0hSQTctVTdHQzByQmRWbVhMSGdyZDlXM1FxaWJLbGlxRmtOelVvMXhTV0VQbksy?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-05T17:00:47+00:00", "published_display": "05 Aug 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report", "summary": "A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to d", "url": "https://www.pharmexec.com/view/senior-source-denies-astrazeneca-bristol-myers-deal-talks", "source_name": "Pharmaceutical Executive", "published_at": "2026-08-05T15:07:25", "published_display": "05 Aug 2026 15:07", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No deal between AstraZeneca and BMS, senior source insists: Reuters", "summary": "Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approx", "url": "https://www.biospace.com/deals/no-deal-between-astrazeneca-and-bms-senior-source-insists-reuters", "source_name": "BioSpace", "published_at": "2026-08-05T15:07:25", "published_display": "05 Aug 2026 15:07", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks", "summary": "A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol", "url": "https://qz.com/astrazeneca-bristol-myers-squibb-merger-talks-denied-080526", "source_name": "Quartz", "published_at": "2026-08-05T13:07:25", "published_display": "05 Aug 2026 13:07", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "'No discussions' over AstraZeneca-Bristol Myers deal, senior source says", "summary": "A senior source close to the matter has stated that there are \"no discussions\" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on po", "url": "https://www.reuters.com/world/no-discussions-over-astrazeneca-bristol-myers-deal-senior-source-says-2026-08-05/", "source_name": "Reuters", "published_at": "2026-08-05T12:05:00", "published_display": "05 Aug 2026 12:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schr\u00f6dinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery", "summary": "Schr\u00f6dinger, Inc. announced a strategic agreement with Bristol Myers Squibb (BMS) to integrate Bunsen, Schr\u00f6dinger's agentic AI co-scientist, into BMS's research operations. This collaboration expands BMS's use of Schr\u00f6dinger's computational platform, enabling enhanced exploratio", "url": "https://finance.yahoo.com/technology/ai/articles/schr-dinger-announces-strategic-collaboration-123000698.html", "source_name": "Market source", "published_at": "2026-08-05T08:30:00", "published_display": "05 Aug 2026 08:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOdDFIOFkzSkNLaUd5T2ZHUGt3eTh6RmtXWWlkTC1zZTYyWktfNU16N1dDalM4SmlabFJaakxpc2N6VU5naVBOYTljenZlcnJaOGd6U3E1ckVHRWN1QVhLandHWllTcHpsN3FrMl8tb3Jyc0c5QkU2ajdsZnlPNEFDeGx2ampJbXV3RTdma1AzUFUwanFSZW1VdnJXTzNWdw?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-04T13:15:03+00:00", "published_display": "04 Aug 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) After AstraZeneca Deal Talk Looks Fully Valued", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-04T12:00:32+00:00", "published_display": "04 Aug 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it \u2018odd\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRmhRR3d6a3c2RC1CQm12WHkyci1mRm0wUGFuT1VNVXVCOXQtdFB1ZGItcFhZMkRBQnhtNlJFb0ttZDNEWmNWem5SM09jNFVmenMzaS10eE41VV95YXJYdTdXYUpYam93QmcwQWR3eElhZzRxdUFWeGVab0lfZHF2aGJXc3MyRVQ2cUJRbXhfX1ZZOE82S3c1aVBxb0hITXZ4ZEtIeGI5ZmJZaFBxUEVLektIM1NQVzNIM290cUxvc0RBOWRHdlBBX255RDU?oc=5", "source_name": "MarketWatch", "published_at": "2026-08-03T20:59:00+00:00", "published_display": "03 Aug 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQT2M4TDRSRXpiQlpyT1c3WGhZZmNkZE11OEx3Zy1Lbzdlb25vYU96dWQ5RWpqd0pRaEpsdk96WFJPUUh4RDRHWmRaQUtsRllGakxlMFBmczllXzB4a3ZfbHFKUVNWOXhjYnlycnQ3UFdjMVFCRXdPWjdKTmJ6OFNDbDh6dGg1Tnk3al82RlNnOVQ2UVk2SUg3eElrZmxRUQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-03T20:54:00+00:00", "published_display": "03 Aug 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQQVNxR2RaMDVGV0pubWNuTTk5QmJzS2RFMTJFWG1OVnFaWGNyWVVpMDl0NlhMV0JwNldzeE90cG9mRk1BWm02ZXd4WWkyNjc3LThpOUVudlQzQnItNThySXhBQ09jQkhtZWhhY19GLU4xOTNNbVNzWkM3OHdrMUE1RFZ3S2JTeGhkLTI3TTZyMzE?oc=5", "source_name": "Barron's", "published_at": "2026-08-03T18:16:00+00:00", "published_display": "03 Aug 2026 18:16", "sentiment": "negative", "sentiment_pct": 22, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOb1pfTGRCdXRIaHVPVzlNWUNWR0VaTy11OU81dWRDLUpSYUctZ2JrVElRelNCVDdvZl9iVlhlNW9vOUVFZVdjY0ZrcTFHam92cUI1T2IyRmo2RDA2eGlPeExPZ1BRNTNkSGFRLVpnNzhVU3JFR2ZYNUVaSWRIYkx1S1pET0lsb3hRbWJ6NFpoVTBBejI4TXhJNUU2eGJyd2dIN3B1VGxzZjh5TzE0WXA2YUltQ2F4OFAxYTJzMHMyOXhsQzhmZkdrODBrNDR3M2s?oc=5", "source_name": "Investopedia", "published_at": "2026-08-03T13:27:23+00:00", "published_display": "03 Aug 2026 13:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Shares Drop, Bristol Myers Squibb\u2019s Climb After Merger Talks Reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQekYwV1hCemJVVnJJa3BYa1k4ZjNjNURUSnhNYjE0TDNBRWhxTnEyVFVzM2hkQTQ1R1RQQzc3NmdJOXNqSHFkbVI1UnRYWThEeXc2eWpldUNOay1mMG1MQktFbW94aGZxajJjVEJsU2pJSUwzWFhTcDl2RjlzdnpmejQzNVVfV2JDRTZZa0o4UnFvZ1pyTng2NjNjdlY2c0cxcTJLN2JnakplU1Zkb0szQnl6VkdHekZJ?oc=5", "source_name": "WSJ", "published_at": "2026-08-03T09:55:00+00:00", "published_display": "03 Aug 2026 09:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Market Chatter: AstraZeneca Weighs $400 Billion Combination With Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQeDRwYzR4SnVPSHNKNmtRZmFUSlNaT1pkUzNQdDNvUElkZVcxcnFwQnM0bVA4aXhIbzNWZFBpU1FUeXYxUHlNLXNqQldCTERqVTdMalAzRVdLaTg0ZEJzcndVNzVUdnRHa2pPRzJFWGtpdmQxeEtqWEFrUUtTQkJicTdEbXdnLWMzcU8xVUVhbC1MR0NuUzljdDRZclhXOTg?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-03T08:50:02+00:00", "published_display": "03 Aug 2026 08:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNUWtrWFNqTm5FaTdVWUpFVWJQeko1dWxFLXptYmhFbjlsSzdBR3VFQUxabnJhZnNTV3ZTT0VYbGpmN0R0UWd4azBLYkdVeHpmdG4tcThRVVprenZHWUFhLUQ5T2RDZnNSa0tHQUpwTmQ2RUR0RUsyaS00bm9RRzZJWWpxTWs0cWdUOE1rMFJZRk9sQ012ZmxieGlvZFdhZnBfYzY5N3oxbDNKbXU3WUYxYnhUTEwtWmEtN1EwOVBWWEZZbkNnOGFISHlaVzV5dUlVYlFJ?oc=5", "source_name": "Morningstar", "published_at": "2026-08-03T07:00:00+00:00", "published_display": "03 Aug 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdC1XTkhHQ2F2bm9lV3E5OE5teFJ1bkFpZHRmWlAyVlZyQjRHdnVtZjQwY3dMUXpwYVBWS0xKblNsaGg1M1EzSFB0REE1MHB4Q2VTY2Utc0xnLUpSRWJzVHZDZFZON3B3ZGlXM3AwLVE5M2cyQVlXLU1GbDM4N2l6djZrbzJmWDFiempRN1hSa1pSOUhvNDc0LVQ1SDdYTm02?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-02T21:14:32+00:00", "published_display": "02 Aug 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQemlpUVZvYjZlTkR4cWxEZ0d4M2thWW5nX3p1X2Rhb1NrQ3ZFc3hfb3JSOGY2WHJRZ0VWVlNDSDV4NEhGaFhMaDFPTG9EejV6TTJLYjdDdTA0QUZ3a0hTZFRqUVA4QVZNVEs1cUVIR0t5QXBoNGVQWUREcEx6bG01M3c3NWZKazJtNnpBU2M3ZzRrS3pfb2xtcU1mU0tUbHV5T1ZYUkNB0gGrAUFVX3lxTE1mektIeHVLTTFZZ2ZWLXJfTkFFQm9xaThmSUJsa0M2OHpzMkoyay1FTUxzOWp5RDF1S20tUV9nOFVWMERqODN1YWZPVnFZTXBZWngxS0FudzlrT1U4NUVTa0F5SjJsV3F5bzdFeE9mUDluai1HZUZDaHFWQTRJTG9MSk8zVUNnSWpOdGpOeDY0RzBkLW8tQ3dkVWt3cVJ6aDBjN1dLZnJieFNDNA?oc=5", "source_name": "CNBC", "published_at": "2026-08-02T20:00:18+00:00", "published_display": "02 Aug 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE9mU1lDM25mUHRBUlFMZXhXOVlWQ3dYenNGMGcyN0V0RV8wZ1YxWm1qUFVPeC15U2I3RndrSUNyZVBqZGtBajdzUzl2R0lOdE5vaW05SVdNblc?oc=5", "source_name": "webull.com", "published_at": "2026-08-01T18:02:52+00:00", "published_display": "01 Aug 2026 18:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Number of Employees 2026 | Employee Count & Headcount Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1oR2lGay1WcE40VXJjMXc2NDBVUm40ZGxZR3JmVFkyNHhUWXAwV2wwMy1yV1FITlo2T2VPT2FKR1EwWmMtT2pQZDVNTGpLcERuS3FUcktkVnRzNnRyZjgybUdGY0lhN1RDck1ab0ZDU3BaZ0JSZUZj?oc=5", "source_name": "Revelio Labs", "published_at": "2026-07-28T17:39:43+00:00", "published_display": "28 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's A Lot To Like About Bristol-Myers Squibb's (NYSE:BMY) Upcoming US$0.63 Dividend", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons to Buy Bristol Myers Squibb Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORUpKQ19CbndxREU4RkxxRkRBazR3NDRiMXVHQVdtYUE5VEdQRlY4dEZWR0JVUk5TZ0NOWXdkVkp4bmtQU1FfNlZLMG5qbmhUa3hWSmF5ekc1NUxqaTFTNEo5ZVU1N1kyaEswaGRMbUEtNVdTZk9zeGloSUZrU2wtR3E4ald0LVFaay1SX1RxTVdNRGEtbFE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNXzBlR1NfeUZwN0piQmR3ejBVdGR6eGFLYVZOZXR5akpES0dma1hxM2ZMWG9LdGU4dzZFa0hxVFZ1VWtTYmUyZlFSMDA1NDZGTW4wdThhckVEWVB5OFZIVjNYYUQ5enM0dDh0UzRGQ1ByNnJ0S3RzazlCRHNDV3l0WUg4ajFFdU84ZUctUjB6Z21vMlB3Uy1RTGhxN2xqc1VzYnBkcVN6dWNzTzlGTVF1M0V0RW9LM1UxMWNTeWhNVG5XMGttOWdSSmstenJNNUdpUnhRVFZCUU5mcldjaVp3clF2RllZQdIB6wFBVV95cUxPblB3NExVYUQ1eC1KS20wUmI2RlRvUmlBNkI1aFZZY1ZqajIyY1dGdVhWV21zSkxNRFVxTDVFVzVIUjZ4MVQ3TTZMYXlGMG1Ib2FwNmJUakF2VGR6YlhiQ25FUFR4cHJlakFkY0U0WTF4YkhCZ3NreDBMUWg4clQ3VHdlRGxUM0JfWUlETWR5LWxFYUxBdFB3N0pydWtRSUliQXNvNHNFbW9ZZTRFWlNKS2NBQ0Z6NzhMQ0lKaHlZNG9hOEFFUlVrWjZfeExiMnNGVXhiTnBwTXpXNS03b3EzbXRMM1Q2SHN2ak5n?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSmZkb01pQU9MRTJPVTJlZ3hnODBvUHRiRlJPalJ6ZXoyNDNvcTMwMTBZMWtpbXJ5TkJnNUp4aENJR1NoTF9BbnVwclpxSzR3WWhZS1Nhdmh2ZF9YXzRGaWpKa0ZNcWltSk1SZVVPMW1MRlBOYTNBMXZTdHJONGtZRDJ1MjZ6YXg1S0lRa0FNbmt6dkpvVVJsZHhkQQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof.", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ0RDUllpczhkczI2MUptb2tNOEFfY0J1eU1PR0dVbTZBdDZJeWdpMnlUUjQxU0E3OUlzS3pUQXYzZ3FOYlZHQjJaOXliVzN3NG9odmhlNzdidlE2Wm1QbDBZS0xtQ3R2TkdCSzBMMkpwYWxyODk1NWY0Y0l4c084OVdkNElfOThqV21JakRSRVZPNjhVMFJaamV6dHAwUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Company (BMY) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1TMloybzBEdXp6dk9ONzI1SXJxR3NXN085Z0k5THk4VTdCNlpoLWZSYzhudTl6a19UX19jX0V0OXM2Y1FhLXFoT00yelZPdDln?oc=5", "source_name": "Market source", "published_at": "2017-05-05T15:31:26+00:00", "published_display": "05 May 2017 15:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "PensionDanmark Pensionsforsikringsaktieselskab Buys 38,596 Shares of Bristol Myers Squibb Company $BMY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8wFBVV95cUxOVm40Y19KdEItcUtrZmpKa3JBeWcxTUM0WVN6YVpOZEc1cEJDN3FyTDlienMwbExlRG91bkwzbEtpdGZkZTBPR1RrdHFaTFo0OTM0UTF1eDdGZ1dYR3M0UnE2SlVwb3ctcnlodmJGSkRTNkNEZTBodUxNUldZcjJRM1dTNjZBd2FkTlZaVVVQQV9penYtTzl4ODJYQi1UT3MzVjFGeUtUTDBhX3F1LTkwUGtvaHA1SWZGY1BBeF9FU0QxZnVRLS1wWElmX3VHMWxEU052bF9iMVgxRWd0c3Jma2ZDRTJoV0x0M1lNX1RTdUxHSGc?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T21:40:05+00:00", "published_display": "07 Aug 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Czech National Bank Purchases 26,627 Shares of Bristol Myers Squibb Company $BMY", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPdC11X2xPQVNnaDltQVpsRWFEbDJPRjNpT0sxdTdTeHlLNXNDWV9qNXFjMlNxdGxXeGV3UUkxSks2alN5MFZsVG56R29OdkltYnN4bFhadHJkXzZIaklBc3YyS0JsRzhEQVdja3FwWDhudlZsSFRyREVIRktZb0cyTlJOVWZZeVBsMEtKTm1xLWF6ek1uZTN0NDAyMTdQdWdIb2V1N3ZfcDl6M3hPNGR3ZHhDcXZkWWdZTHlsbG9qTmstTnVxRTJ3a25HN21iZDlaOWxCYWpR?oc=5", "source_name": "MarketBeat", "published_at": "2026-08-07T10:52:41+00:00", "published_display": "07 Aug 2026 10:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Replimune's skin cancer drug after prior rejections", "summary": "The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Bio", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-replimunes-skin-cancer-drug-2026-08-06/", "source_name": "Reuters", "published_at": "2026-08-06T20:26:00", "published_display": "06 Aug 2026 20:26", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deal or No Deal, AstraZeneca Stock Is a Bargain", "summary": "AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are dow", "url": "https://www.wsj.com/finance/deal-or-no-deal-astrazeneca-stock-is-a-bargain-b9ce6b31", "source_name": "WSJ", "published_at": "2026-08-06T09:39:46", "published_display": "06 Aug 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beyond the Megamerger: How Rumored AstraZeneca\u2013BMS Discussions Signal a New Era of Pharmaceutical Competition", "summary": "Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabiliti", "url": "https://www.pharmexec.com/view/megamerger-astrazeneca-bms-pharmaceutical-competition", "source_name": "Pharmaceutical Executive", "published_at": "2026-08-06T07:07:18", "published_display": "06 Aug 2026 07:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schr\u00f6dinger (SDGR) Is Up 8.5% After AI Co\u2011Scientist Deal With BMS And Q2 Profitability Shift \u2013 Has The Bull Case Changed?", "summary": "Schr\u00f6dinger, Inc. reported strong Q2 2026 results with a shift to profitability and a significant expansion of its AI co-scientist collaboration with Bristol Myers Squibb. This deal, involving the new agentic AI Bunsen, reinforces the company's AI-driven growth ambitions and its ", "url": "https://ca.finance.yahoo.com/news/schr-dinger-sdgr-8-5-060952292.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-08-06T06:12:34", "published_display": "06 Aug 2026 06:12", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Looks Reasonable Below Fair Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-06T04:48:41+00:00", "published_display": "06 Aug 2026 04:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sources quash rumours of an AZ/BMS mega-merger", "summary": "Reports from Reuters indicate there is no truth to the rumors of a potential $400 billion mega-merger between AstraZeneca (AZ) and Bristol Myers Squibb (BMS). A senior source close to the matter confirmed that no such deal was ever contemplated, nor are there ongoing discussions ", "url": "https://pharmaphorum.com/news/sources-quash-rumours-azbms-mega-merger", "source_name": "pharmaphorum", "published_at": "2026-08-06T05:37:15", "published_display": "06 Aug 2026 05:37", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation", "summary": "AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, wh", "url": "https://www.pymnts.com/cpi-posts/astrazeneca-bristol-myers-dismiss-merger-talk-speculation/", "source_name": "PYMNTS.com", "published_at": "2026-08-06T03:07:17", "published_display": "06 Aug 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Co (BMY) Stock Down 3.4% but Still Overvalued -- GF Score: 71/100", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOUEdUOWJjSUFNaGNrM2dCb2xieDhHcnRPcjRrb1MyNGV2YWtxRDNhZ044TmIyd1RxWDdHT3pMWVQ4bnh4ZENOazZQUGg4dEZPNko2bUlZVzJIQjcwLTNWbHRtamhrNnZETmNfVnZSbWpLSTg1dlRqNUJ1M3NFcWZBQVYwNW9VdjgwUXJReENFS3JfaTNFQVhBd0RoclhjZVJVVmxwWjJ2TEIwNi1TaElTRlI3c1Rfdw?oc=5", "source_name": "GuruFocus", "published_at": "2026-08-05T21:35:11+00:00", "published_display": "05 Aug 2026 21:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Company (BMY) Stock Forecasts", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxOanE0TldodlF3REExQUR3OUprMElfY29lU0tGaDlFNmJvU2xHSTI1VGE2OFpwdjYwbTRUQUVMUGEzSWNMVHVsYXdVbXdhVFo3QzAxMlRzcVJiT0hSQTctVTdHQzByQmRWbVhMSGdyZDlXM1FxaWJLbGlxRmtOelVvMXhTV0VQbksy?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-05T17:00:47+00:00", "published_display": "05 Aug 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report", "summary": "A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to d", "url": "https://www.pharmexec.com/view/senior-source-denies-astrazeneca-bristol-myers-deal-talks", "source_name": "Pharmaceutical Executive", "published_at": "2026-08-05T15:07:25", "published_display": "05 Aug 2026 15:07", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "No deal between AstraZeneca and BMS, senior source insists: Reuters", "summary": "Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approx", "url": "https://www.biospace.com/deals/no-deal-between-astrazeneca-and-bms-senior-source-insists-reuters", "source_name": "BioSpace", "published_at": "2026-08-05T15:07:25", "published_display": "05 Aug 2026 15:07", "sentiment": "negative", "sentiment_pct": 38, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks", "summary": "A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol", "url": "https://qz.com/astrazeneca-bristol-myers-squibb-merger-talks-denied-080526", "source_name": "Quartz", "published_at": "2026-08-05T13:07:25", "published_display": "05 Aug 2026 13:07", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "'No discussions' over AstraZeneca-Bristol Myers deal, senior source says", "summary": "A senior source close to the matter has stated that there are \"no discussions\" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on po", "url": "https://www.reuters.com/world/no-discussions-over-astrazeneca-bristol-myers-deal-senior-source-says-2026-08-05/", "source_name": "Reuters", "published_at": "2026-08-05T12:05:00", "published_display": "05 Aug 2026 12:05", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Schr\u00f6dinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery", "summary": "Schr\u00f6dinger, Inc. announced a strategic agreement with Bristol Myers Squibb (BMS) to integrate Bunsen, Schr\u00f6dinger's agentic AI co-scientist, into BMS's research operations. This collaboration expands BMS's use of Schr\u00f6dinger's computational platform, enabling enhanced exploratio", "url": "https://finance.yahoo.com/technology/ai/articles/schr-dinger-announces-strategic-collaboration-123000698.html", "source_name": "Market source", "published_at": "2026-08-05T08:30:00", "published_display": "05 Aug 2026 08:30", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Company (BMY) Hit a 52 Week High, Can the Run Continue?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOdDFIOFkzSkNLaUd5T2ZHUGt3eTh6RmtXWWlkTC1zZTYyWktfNU16N1dDalM4SmlabFJaakxpc2N6VU5naVBOYTljenZlcnJaOGd6U3E1ckVHRWN1QVhLandHWllTcHpsN3FrMl8tb3Jyc0c5QkU2ajdsZnlPNEFDeGx2ampJbXV3RTdma1AzUFUwanFSZW1VdnJXTzNWdw?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-04T13:15:03+00:00", "published_display": "04 Aug 2026 13:15", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) After AstraZeneca Deal Talk Looks Fully Valued", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNeXduNV9NUWo2cGFwVVA5VXVYWFlMUGsyZFdMdUw0UHNZOVFsZjllUGRUMUdUQzd5YW9lNUl6QUNqOUZNLTBuWkx4bmdaQThNWGF4UnpNZzd5REQ2NVZLS2xuYWtOdWxqOUtrYTZSSWtvODNGb0JPTkoyWlRWdXU3alN0QlA0UUlMelZxYmhXLVZSSzNSU2xwSVgtM2RnSDQ0T0I3OVc4dkExNE5zVEhHdlNSbDM2a1l4cHprSGdnVFU0Um1aakpQc1hWaGxBelNNR3lvTFA0eUptQ2lGMkhQVHA3M1JFUdIB6wFBVV95cUxOVzdRSWFua0lMajNuRzZxcU5Dd0hfZmVnRTJPMzZ4NHltOVB5N29yQUtnbHJnM2tJc1ZMVWppNm50Skl2UUlmMmJEVEJfQ3pscjN3N2JfYlFQRWRRSTVJU0dMOWZBUkhGM19Ld2ZHVFNmQXl5RG9naWtqN2VxYjNaYTVXaERhdVozZS1jb2lBNXFDYzQ3X2c4NlNyXzdvYk5SekZ4S29mZE5CV1JPZ0tTMXNkWWhUMVNGbllIV1BhOUVXNGQ0NFB1MHZ6MVJNUWNlN3FCQkZsSkxDT2VYWDY1WjFsSXVhZWJwWFhz?oc=5", "source_name": "simplywall.st", "published_at": "2026-08-04T12:00:32+00:00", "published_display": "04 Aug 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it \u2018odd\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQRmhRR3d6a3c2RC1CQm12WHkyci1mRm0wUGFuT1VNVXVCOXQtdFB1ZGItcFhZMkRBQnhtNlJFb0ttZDNEWmNWem5SM09jNFVmenMzaS10eE41VV95YXJYdTdXYUpYam93QmcwQWR3eElhZzRxdUFWeGVab0lfZHF2aGJXc3MyRVQ2cUJRbXhfX1ZZOE82S3c1aVBxb0hITXZ4ZEtIeGI5ZmJZaFBxUEVLektIM1NQVzNIM290cUxvc0RBOWRHdlBBX255RDU?oc=5", "source_name": "MarketWatch", "published_at": "2026-08-03T20:59:00+00:00", "published_display": "03 Aug 2026 20:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQT2M4TDRSRXpiQlpyT1c3WGhZZmNkZE11OEx3Zy1Lbzdlb25vYU96dWQ5RWpqd0pRaEpsdk96WFJPUUh4RDRHWmRaQUtsRllGakxlMFBmczllXzB4a3ZfbHFKUVNWOXhjYnlycnQ3UFdjMVFCRXdPWjdKTmJ6OFNDbDh6dGg1Tnk3al82RlNnOVQ2UVk2SUg3eElrZmxRUQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-03T20:54:00+00:00", "published_display": "03 Aug 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQQVNxR2RaMDVGV0pubWNuTTk5QmJzS2RFMTJFWG1OVnFaWGNyWVVpMDl0NlhMV0JwNldzeE90cG9mRk1BWm02ZXd4WWkyNjc3LThpOUVudlQzQnItNThySXhBQ09jQkhtZWhhY19GLU4xOTNNbVNzWkM3OHdrMUE1RFZ3S2JTeGhkLTI3TTZyMzE?oc=5", "source_name": "Barron's", "published_at": "2026-08-03T18:16:00+00:00", "published_display": "03 Aug 2026 18:16", "sentiment": "negative", "sentiment_pct": 22, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxOb1pfTGRCdXRIaHVPVzlNWUNWR0VaTy11OU81dWRDLUpSYUctZ2JrVElRelNCVDdvZl9iVlhlNW9vOUVFZVdjY0ZrcTFHam92cUI1T2IyRmo2RDA2eGlPeExPZ1BRNTNkSGFRLVpnNzhVU3JFR2ZYNUVaSWRIYkx1S1pET0lsb3hRbWJ6NFpoVTBBejI4TXhJNUU2eGJyd2dIN3B1VGxzZjh5TzE0WXA2YUltQ2F4OFAxYTJzMHMyOXhsQzhmZkdrODBrNDR3M2s?oc=5", "source_name": "Investopedia", "published_at": "2026-08-03T13:27:23+00:00", "published_display": "03 Aug 2026 13:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca Shares Drop, Bristol Myers Squibb\u2019s Climb After Merger Talks Reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQekYwV1hCemJVVnJJa3BYa1k4ZjNjNURUSnhNYjE0TDNBRWhxTnEyVFVzM2hkQTQ1R1RQQzc3NmdJOXNqSHFkbVI1UnRYWThEeXc2eWpldUNOay1mMG1MQktFbW94aGZxajJjVEJsU2pJSUwzWFhTcDl2RjlzdnpmejQzNVVfV2JDRTZZa0o4UnFvZ1pyTng2NjNjdlY2c0cxcTJLN2JnakplU1Zkb0szQnl6VkdHekZJ?oc=5", "source_name": "WSJ", "published_at": "2026-08-03T09:55:00+00:00", "published_display": "03 Aug 2026 09:55", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Market Chatter: AstraZeneca Weighs $400 Billion Combination With Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQeDRwYzR4SnVPSHNKNmtRZmFUSlNaT1pkUzNQdDNvUElkZVcxcnFwQnM0bVA4aXhIbzNWZFBpU1FUeXYxUHlNLXNqQldCTERqVTdMalAzRVdLaTg0ZEJzcndVNzVUdnRHa2pPRzJFWGtpdmQxeEtqWEFrUUtTQkJicTdEbXdnLWMzcU8xVUVhbC1MR0NuUzljdDRZclhXOTg?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-03T08:50:02+00:00", "published_display": "03 Aug 2026 08:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca and Bristol-Myers Squibb: Megamerger Reports Leave Us Scratching Our Heads", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNUWtrWFNqTm5FaTdVWUpFVWJQeko1dWxFLXptYmhFbjlsSzdBR3VFQUxabnJhZnNTV3ZTT0VYbGpmN0R0UWd4azBLYkdVeHpmdG4tcThRVVprenZHWUFhLUQ5T2RDZnNSa0tHQUpwTmQ2RUR0RUsyaS00bm9RRzZJWWpxTWs0cWdUOE1rMFJZRk9sQ012ZmxieGlvZFdhZnBfYzY5N3oxbDNKbXU3WUYxYnhUTEwtWmEtN1EwOVBWWEZZbkNnOGFISHlaVzV5dUlVYlFJ?oc=5", "source_name": "Morningstar", "published_at": "2026-08-03T07:00:00+00:00", "published_display": "03 Aug 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca slides 7% after report of merger talks with Bristol Myers Squibb", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPdC1XTkhHQ2F2bm9lV3E5OE5teFJ1bkFpZHRmWlAyVlZyQjRHdnVtZjQwY3dMUXpwYVBWS0xKblNsaGg1M1EzSFB0REE1MHB4Q2VTY2Utc0xnLUpSRWJzVHZDZFZON3B3ZGlXM3AwLVE5M2cyQVlXLU1GbDM4N2l6djZrbzJmWDFiempRN1hSa1pSOUhvNDc0LVQ1SDdYTm02?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-08-02T21:14:32+00:00", "published_display": "02 Aug 2026 21:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQemlpUVZvYjZlTkR4cWxEZ0d4M2thWW5nX3p1X2Rhb1NrQ3ZFc3hfb3JSOGY2WHJRZ0VWVlNDSDV4NEhGaFhMaDFPTG9EejV6TTJLYjdDdTA0QUZ3a0hTZFRqUVA4QVZNVEs1cUVIR0t5QXBoNGVQWUREcEx6bG01M3c3NWZKazJtNnpBU2M3ZzRrS3pfb2xtcU1mU0tUbHV5T1ZYUkNB0gGrAUFVX3lxTE1mektIeHVLTTFZZ2ZWLXJfTkFFQm9xaThmSUJsa0M2OHpzMkoyay1FTUxzOWp5RDF1S20tUV9nOFVWMERqODN1YWZPVnFZTXBZWngxS0FudzlrT1U4NUVTa0F5SjJsV3F5bzdFeE9mUDluai1HZUZDaHFWQTRJTG9MSk8zVUNnSWpOdGpOeDY0RzBkLW8tQ3dkVWt3cVJ6aDBjN1dLZnJieFNDNA?oc=5", "source_name": "CNBC", "published_at": "2026-08-02T20:00:18+00:00", "published_display": "02 Aug 2026 20:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWEFVX3lxTE9mU1lDM25mUHRBUlFMZXhXOVlWQ3dYenNGMGcyN0V0RV8wZ1YxWm1qUFVPeC15U2I3RndrSUNyZVBqZGtBajdzUzl2R0lOdE5vaW05SVdNblc?oc=5", "source_name": "webull.com", "published_at": "2026-08-01T18:02:52+00:00", "published_display": "01 Aug 2026 18:02", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb Number of Employees 2026 | Employee Count & Headcount Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE1oR2lGay1WcE40VXJjMXc2NDBVUm40ZGxZR3JmVFkyNHhUWXAwV2wwMy1yV1FITlo2T2VPT2FKR1EwWmMtT2pQZDVNTGpLcERuS3FUcktkVnRzNnRyZjgybUdGY0lhN1RDck1ab0ZDU3BaZ0JSZUZj?oc=5", "source_name": "Revelio Labs", "published_at": "2026-07-28T17:39:43+00:00", "published_display": "28 Jul 2026 17:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There's A Lot To Like About Bristol-Myers Squibb's (NYSE:BMY) Upcoming US$0.63 Dividend", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "3 Reasons to Buy Bristol Myers Squibb Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxORUpKQ19CbndxREU4RkxxRkRBazR3NDRiMXVHQVdtYUE5VEdQRlY4dEZWR0JVUk5TZ0NOWXdkVkp4bmtQU1FfNlZLMG5qbmhUa3hWSmF5ekc1NUxqaTFTNEo5ZVU1N1kyaEswaGRMbUEtNVdTZk9zeGloSUZrU2wtR3E4ald0LVFaay1SX1RxTVdNRGEtbFE?oc=5", "source_name": "The Motley Fool", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Reports Strong Myeloma Trial Results And Early CAR T Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol Myers Squibb (BMY) Stock Could Be 12.2% Undervalued on Pipeline and Margin Hopes", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSmZkb01pQU9MRTJPVTJlZ3hnODBvUHRiRlJPalJ6ZXoyNDNvcTMwMTBZMWtpbXJ5TkJnNUp4aENJR1NoTF9BbnVwclpxSzR3WWhZS1Nhdmh2ZF9YXzRGaWpKa0ZNcWltSk1SZVVPMW1MRlBOYTNBMXZTdHJONGtZRDJ1MjZ6YXg1S0lRa0FNbmt6dkpvVVJsZHhkQQ?oc=5", "source_name": "finance.yahoo.com", "published_at": "2026-06-17T07:00:00+00:00", "published_display": "17 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Made Its Pipeline Case at BofA. Now Comes the Proof.", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQZ0RDUllpczhkczI2MUptb2tNOEFfY0J1eU1PR0dVbTZBdDZJeWdpMnlUUjQxU0E3OUlzS3pUQXYzZ3FOYlZHQjJaOXliVzN3NG9odmhlNzdidlE2Wm1QbDBZS0xtQ3R2TkdCSzBMMkpwYWxyODk1NWY0Y0l4c084OVdkNElfOThqV21JakRSRVZPNjhVMFJaamV6dHAwUQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bristol-Myers Squibb Company (BMY) stock price, news, quote and history", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTE1TMloybzBEdXp6dk9ONzI1SXJxR3NXN085Z0k5THk4VTdCNlpoLWZSYzhudTl6a19UX19jX0V0OXM2Y1FhLXFoT00yelZPdDln?oc=5", "source_name": "Market source", "published_at": "2017-05-05T15:31:26+00:00", "published_display": "05 May 2017 15:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 114, "total_relevant": 35, "sentiment_summary": {"positive": 8, "negative": 4, "neutral": 23, "score": 51, "total": 35, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "deals", "primary_label": "Deals and strategy", "confidence": 76, "events": [{"event": "deals", "label": "Deals and strategy", "weight": 10.35, "count": 15}, {"event": "general", "label": "Market update", "weight": 8.05, "count": 14}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 65.31, "latest_week": "2026-07-31", "one_week_move": 5.2, "four_week_move": 12.4, "twelve_week_move": 17.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.312438, "market_dynamics_buy_signal": false, "relative_strength": 13.055232, "fair_value_gap": 32.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.2492, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.2% over one week, +12.4% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 58, "badges": [], "opportunities": [], "risks": [], "event_label": "Deals and strategy", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "finance.yahoo.com", "count": 6}, {"label": "simplywall.st", "count": 4}, {"label": "MarketBeat", "count": 2}, {"label": "Reuters", "count": 2}, {"label": "WSJ", "count": 2}, {"label": "Pharmaceutical Executive", "count": 2}, {"label": "Market source", "count": 2}, {"label": "Yahoo! Finance Canada", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Deals and strategy", "count": 15}, {"label": "Market update", "count": 14}, {"label": "Earnings", "count": 4}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Deals and strategy", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "8", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+5.2% over one week, +12.4% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "PensionDanmark Pensionsforsikringsaktieselskab Buys 38,596 Shares of Bristol Myers Squibb Company $BMY"}], "updated_at": "2026-08-08T08:40:18.054302+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}